News Updates
Scope

Fri, May 22, 2026

1 updates
ABVX
4:05 PM

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Interim intent to treat (“ITT”) analysis from Study 108 supports strong

Interim Data • Phase 2presentation Fri, Jan 9, 2026abivax.com

Mon, May 11, 2026

1 updates
ABVX
4:05 PM

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the

abivax.com

Tue, May 5, 2026

1 updates

Wed, Apr 22, 2026

1 updates
ABVX
4:05 PM

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST –

Presentation / Abstract • Phase 3abivax.com

Mon, Apr 20, 2026

1 updates

Wed, Apr 1, 2026

1 updates

Mon, Mar 23, 2026

1 updates